First Trust Nasdaq Pharmaceuticals ETF
Pfizer’s Vaccines: A Look at Their Market Performance
In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.
Allergan’s Q3 2018 Earnings: Analysts’ Estimates
Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.
Pfizer: Analysts Expect Revenue Growth in Q3
Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.
Eli Lilly’s Stock Performance and Estimates for Q3 2018
Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”
Pfizer’s Revenue and EPS Growth Rate
Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.
Allergan’s First Medical Aesthetics Innovation Center in China
Allergan’s total investment in the Medical Aesthetics and Innovation Center is ~$14.7 million.
How Does Sage Therapeutics’ Product Portfolio Look in September?
Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
A Look at Eli Lilly’s New Products in Q2 2018
Eli Lilly and Company’s (LLY) new products portfolio includes new products that have been launched since 2014.
Allergan’s International Business Segment in Q2 2018
Allergan’s International Business segment reported revenue of $949 million in the second quarter.
Sage Therapeutics’ NMDA Receptor–Based Products
Sage Therapeutics developed SAGE-718, which targets the NMDA Receptor.
SAGE Therapeutics’ Stock Performance and Estimates in June
SAGE Therapeutics’ stock price has risen nearly 111.5% in the last 12 months.
Sage’s Brexanolone IV: FDA Grants Priority Review
On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.
How Merck’s Animal Health Segment Did in 1Q18
In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.
How Analysts View Allergan after Its 1Q18 Earnings
Allergan (AGN) surpassed Wall Street analysts’ estimates, reporting earnings per share of $3.74 on revenues of $3.7 billion during 1Q18.
Wall Street Recommendations for Merck & Co. before Earnings
Wall Street analysts expect Merck & Co.’s (MRK) top line to increase 7.1% to $10.1 billion for 1Q18, compared to revenues of $9.4 billion for 1Q17.
These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.
What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.
Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.
How Bristol-Myers Squibb Stock Performed in 1Q18
Bristol-Myers Squibb stock has fallen ~1.6% in 1Q18, and its stock has fallen ~0.6% YTD (year-to-date) as of April 6, 2018.
Eli Lilly’s Segment-by-Segment Performance in 4Q17
Eli Lilly and Company’s (LLY) products are classified into two business segments: Human Pharmaceuticals and Animal Health.
Wall Street Analysts’ Recommendations for JNJ in January 2018
Wall Street analysts expect Johnson & Johnson to generate EPS of $2.01 on revenues of ~$19.4 billion in 1Q18 for 9.2% growth in revenues compared to 1Q17.
Pfizer’s 4Q17 Estimates: Products with Lower Sales
In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.
Wall Street Recommendations for Mylan in January 2018
As we discussed earlier in this series, Mylan (MYL) reported revenues of $2.98 billion in 3Q17, a 2.3% decline in revenues compared to $3.06 billion in 3Q16.
Analysts’ Recommendations for Pfizer 4Q17
Analysts’ estimates Between 4Q16 and 4Q17, Wall Street analysts expect Pfizer’s (PFE) revenue to rise ~0.8% to $13.72 billion from $13.63 billion. However, analysts expect it to fall ~0.5% to $52.6 billion in 2017 from $52.8 billion in 2016. They expect Pfizer to see EPS (earnings per share) of $0.56 in 4Q17 and $2.59 in 2017. Analysts’ ratings The above chart shows analysts’ recommendations […]
Eli Lilly’s New Products Portfolio in 3Q17
Eli Lilly and Co.’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.
How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17
In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.
How Pfizer’s Established Products Have Performed
In 3Q17, Pfizer’s (PFE) Lipitor reported revenues of $491 million, a ~16% increase on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Bristol-Myers Squibb’s Valuations after Its 3Q17 Earnings
Of the 22 analysts covering Bristol-Myers Squibb, nine analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.”
Analysts’ Ratings and Recommendations for Johnson & Johnson
JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.
Bristol-Myers Squibb’s Immunoscience Products
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.
How Johnson & Johnson’s Medical Devices Segment Performed
Johnson & Johnson’s (JNJ) medical devices segment includes cardiovascular care, diabetes care, orthopedics, surgery, and vision care products.
These Pfizer’s Products Are Now Losing Market Share
Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.
What Are Sage Therapeutics’ GABA Receptor Products?
The products under development for the treatment of life-threatening central nervous system (or CNS) disorders in Sage Therapeutics’ (SAGE) portfolio are either based on GABA or NMDA receptor systems.
Behind Merck’s Animal Health Segment Performance in 2Q17
Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.
Performance of Eli Lilly’s Business Segments in 2Q17
The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues.
What to Expect from Pfizer’s Biosimilars Business
In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.
Major Developments for Johnson & Johnson in 2Q17
Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]
Pfizer’s Valuation after 2Q17 Earnings
Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.
Johnson & Johnson’s Revenue Trend in 3Q16
In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues.
Bristol-Myers Squibb’s 3Q16 Estimates: Oncology Segment
Opdivo is a human PD-1 blocking antibody used in lung cancer and melanoma treatments. Opdivo is part of BMY’s alliance with Ono Pharmaceutical.
Good News: Johnson & Johnson’s 3Q16 Revenues Expected to Rise
Analysts expect Johnson & Johnson’s (JNJ) 3Q16 revenues to rise 3.7% to $17.7 billion. The expectation comes on the back of an increase in sales of its blockbuster drugs.